Literature DB >> 23378628

Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

Faraz Kazmi1, Tiffini Hensley, Chad Pope, Ryan S Funk, Greg J Loewen, David B Buckley, Andrew Parkinson.   

Abstract

Lipophilic (logP > 1) and amphiphilic drugs (also known as cationic amphiphilic drugs) with ionizable amines (pKa > 6) can accumulate in lysosomes, a process known as lysosomal trapping. This process contributes to presystemic extraction by lysosome-rich organs (such as liver and lung), which, together with the binding of lipophilic amines to phospholipids, contributes to the large volume of distribution characteristic of numerous cardiovascular and central nervous system drugs. Accumulation of lipophilic amines in lysosomes has been implicated as a cause of phospholipidosis. Furthermore, elevated levels of lipophilic amines in lysosomes can lead to high organ-to-blood ratios of drugs that can be mistaken for active drug transport. In the present study, we describe an in vitro fluorescence-based method (using the lysosome-specific probe LysoTracker Red) to identify lysosomotropic agents in immortalized hepatocytes (Fa2N-4 cells). A diverse set of compounds with various physicochemical properties were tested, such as acids, bases, and zwitterions. In addition, the partitioning of the nonlysosomotropic atorvastatin (an anion) and the lysosomotropics propranolol and imipramine (cations) were quantified in Fa2N-4 cells in the presence or absence of various lysosomotropic or nonlysosomotropic agents and inhibitors of lysosomal sequestration (NH4Cl, nigericin, and monensin). Cellular partitioning of propranolol and imipramine was markedly reduced (by at least 40%) by NH4Cl, nigericin, or monensin. Lysosomotropic drugs also inhibited the partitioning of propranolol by at least 50%, with imipramine partitioning affected to a lesser degree. This study demonstrates the usefulness of immortalized hepatocytes (Fa2N-4 cells) for determining the lysosomal sequestration of lipophilic amines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378628      PMCID: PMC3608459          DOI: 10.1124/dmd.112.050054

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  35 in total

1.  Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs.

Authors:  Gerhard A Siebert; Daniel Y Hung; Ping Chang; Michael S Roberts
Journal:  J Pharmacol Exp Ther       Date:  2003-10-17       Impact factor: 4.030

Review 2.  The potential role of lysosomes in tissue distribution of weak bases.

Authors:  A C MacIntyre; D J Cutler
Journal:  Biopharm Drug Dispos       Date:  1988 Nov-Dec       Impact factor: 1.627

3.  Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction.

Authors:  Ryan S Funk; Jeffrey P Krise
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

Review 4.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

5.  Inhibition of purified lysosomal phospholipase A1 by beta-adrenoceptor blockers.

Authors:  A S Pappu; P J Yazaki; K Y Hostetler
Journal:  Biochem Pharmacol       Date:  1985-02-15       Impact factor: 5.858

6.  Uptake of propranolol by the lung and its displacement by other drugs: involvement of the alveolar macrophage.

Authors:  D M Kornhauser; R E Vestal; D G Shand
Journal:  Pharmacology       Date:  1980       Impact factor: 2.547

7.  Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60.

Authors:  Muralikrishna Duvvuri; Yuping Gong; Dev Chatterji; Jeffrey P Krise
Journal:  J Biol Chem       Date:  2004-06-03       Impact factor: 5.157

8.  Active uptake of propranolol by isolated rabbit alveolar macrophages and its inhibition by other basic amines.

Authors:  R E Vestal; D M Kornhauser; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1980-07       Impact factor: 4.030

9.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.

Authors:  T Yoshimori; A Yamamoto; Y Moriyama; M Futai; Y Tashiro
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

View more
  77 in total

1.  Lysosome-Targeted Bioprobes for Sequential Cell Tracking from Macroscopic to Microscopic Scales.

Authors:  G Kate Park; Jeong Heon Lee; Andrew Levitz; Georges El Fakhri; Nathaniel S Hwang; Maged Henary; Hak Soo Choi
Journal:  Adv Mater       Date:  2019-02-10       Impact factor: 30.849

2.  Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates.

Authors:  Brian C Ferslew; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2014-02-22       Impact factor: 4.849

3.  Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Jason S Pierce; Barbara Rembiesa; Silva Terzieva; Cungui Mao; Ruijuan Xu; Bill Wu; Christopher J Clarke; Benjamin Newcomb; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2014-10-22       Impact factor: 3.641

4.  Screening-based translation of public research encounters painful problems.

Authors:  Jonathan B Baell
Journal:  ACS Med Chem Lett       Date:  2015-02-09       Impact factor: 4.345

5.  TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer.

Authors:  Jens T Siveke; Smiths S Lueong; Ben Zhao; Laura Dierichs; Jiang-Ning Gu; Marija Trajkovic-Arsic; Ralf Axel Hilger; Konstantinos Savvatakis; Silvia Vega-Rubin-de-Celis; Sven-Thorsten Liffers; Samuel Peña-Llopis; Diana Behrens; Stephan Hahn
Journal:  Cell Death Discov       Date:  2020-03-11

Review 6.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

7.  The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.

Authors:  Juan Manuel Coya; Alexandra Maure; Anne Biton; Roland Brosch; Brigitte Gicquel; Alexandre Giraud-Gatineau; Michael Thomson; Elliott M Bernard; Jade Marrec; Maximiliano G Gutierrez; Gérald Larrouy-Maumus; Ludovic Tailleux
Journal:  Elife       Date:  2020-05-04       Impact factor: 8.140

8.  Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer.

Authors:  Rui Li; Yi-An Bi; Yurong Lai; Kiyohiko Sugano; Stefanus J Steyn; Patrick E Trapa; Li Di
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

9.  Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.

Authors:  Xu Zhu; Sheryl Trueman; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-08-01       Impact factor: 2.745

10.  Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.

Authors:  Adam Rolt; Derek Le; Zongyi Hu; Amy Q Wang; Pranav Shah; Marc Singleton; Emma Hughes; Andrés E Dulcey; Shanshan He; Michio Imamura; Takuro Uchida; Kazuaki Chayama; Xin Xu; Juan J Marugan; T Jake Liang
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.